Tradestie Institutional Equity Comparison Engine

CVM vs BGMSP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CVM Overall Edge

CVM Captures Institutional Edge (3โ€“1 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cel-Sci Corporation (CVM) driven by superior Valuation, Growth & Margin, Momentum & Technical while BGMSP counters with relative strength in Options & Structure. Fundamentally, CVM trades at 23.0x Forward P/E with 0.0% operating margin (-62.7% YoY revenue) versus BGMSP at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against BGMSP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner CVM
CVM 23.0x vs BGMSP N/M Fwd P/E
Growth & Margin Winner CVM
Op Margin 0.0% vs N/A ยท YoY -62.7% vs N/A
Momentum & Technical Winner CVM
1Y -77.5% vs -72.6% ยท 52W Pos 10% vs 0%
Options & Structure Winner BGMSP
BREAKDOWN (N/A IV) vs UNCLASSIFIED (N/A IV)
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
1M Return -11.17%
1Y Return -77.48%
Forward P/E 23.0x
Unified AI Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
BGMSP US Equity
BGMSP
Institutional Equity
$1.44
-39.75% 1D
Market Cap N/A
1M Return -60.98%
1Y Return -72.57%
Forward P/E N/M
Unified AI Score
42.7 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CVM -77.48% BGMSP -72.57% Spread: +24.37 pp (CVM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CVM TTM Op. Margin: 0.0% BGMSP TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CVM vs BGMSP. Trailing 12-month operating profitability (CVM 0.0% vs BGMSP N/A) and valuation multiples (CVM 23.0x vs BGMSP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CVM (10) vs BGMSP (0)
Institutional Metric CVM BGMSP Criterion Row Winner
Market Capitalization Scale $20.9M N/A Larger Scale CVM
Trailing P/E Ratio Valuation 23.0x N/M Lower Multiple CVM
Forward P/E Ratio Valuation 23.0x N/M Lower Multiple CVM
Revenue Growth (YoY) Growth -62.7% N/A Higher Growth CVM
Operating Margin (TTM) Profitability 0.0% N/A Higher Margin CVM
Net Profit Margin Profitability 0.0% N/A Higher Margin CVM
Return on Equity (ROE) Capital Efficiency -252.5% N/A Higher ROE CVM
52-Week Range Position Momentum 10% ($1โ€“$8) 0% ($1โ€“$14) Stronger Trend CVM
Beta / 30D Volatility Risk Regime 0.65ฮฒ ยท 120% Vol 0.59ฮฒ ยท 201% Vol Lower Realized Risk CVM
Unified Institutional Score Composite Signal 56.6 / 100 (HOLD) 42.7 / 100 (HOLD) Higher Composite CVM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CVM vs BGMSP Buy Guide
CVM BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CVM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BGMSP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BGMSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CVM nor BGMSP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.